Pascal Touchon - 01 Mar 2022 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Mar 2022, 18:02:34 UTC
Prior SEC filing
18 Nov 2021
Next SEC filing
19 May 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ David Tucker, Attorney-in-Fact for Pascal Touchon

Key filing fact

Pascal Touchon filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 03 Mar 2022.

Key facts

  • This page summarizes Pascal Touchon's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 03 Mar 2022, 18:02.

Change

  • Previous filing in this sequence was filed on 18 Nov 2021.
  • Current net transaction value: -$87,009.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATRA transaction

Common Stock

Award

Transaction value
$0
Shares
+180,565
Change %
+55%
Price
$0.000000
Shares after
509,054
Date
01 Mar 2022
Ownership
Direct
Footnotes
F1
ATRA transaction

Common Stock

Sale

Transaction value
$87,009
Shares
-8,828
Change %
-1.7%
Price
$9.86
Shares after
500,226
Date
01 Mar 2022
Ownership
Direct
Footnotes
F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATRA transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+339,419
Change %
Price
$0.000000
Shares after
339,419
Date
01 Mar 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
339,419
Exercise price
$10.21
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year.

Footnote F2

Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units.

Footnote F3

The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 1, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.

Footnote F4

1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .